Issue 73

Accessing psilocybin in the UK

At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across Europe.

Accelerating the adoption and accessibility of psychedelic healthcare is crucial to drive innovation in mental healthcare and improved patient outcomes worldwide.

The discovery and development of psychedelic medicines in Europe are currently hindered by regulations that restrict their access. Despite a mounting body of clinical evidence demonstrating its medical efficacy, psilocybin remains a Schedule 1 substance in the UK.

The Conservative Drug Policy Reform Group (CDPRG) is championing the campaign to reschedule psilocybin, with Chair and Member of Parliament Crispin Blunt speaking at the PSYCH Symposium on Wednesday, 11 May.

Ahead of the seminal event, PSYCH spoke with Blunt and Timmy Davis, Psilocybin Rescheduling Project Manager at the CDPRG, on the need to facilitate access to psilocybin in the UK for medical research.

INSIDE LONDON'S FIRST PSYCHEDELIC PSYCHOTHERAPY CLINIC

Professor Nutt speaks to the London Evening Standard as Awakn’s psychedelic healthcare clinic gain Care Quality Commission approval.

CALIFORNIA ACTIVISTS DROP 2022 PSILOCYBIN LEGALISATION INITIATIVE

The measure failed to gain enough support for November’s ballot, gathering 300,000 signatures – roughly half that required.

BUSINESS AND INVESTMENT

Demand for 5-MeO-DMT endangers Sonoran Desert toad.

Irwin Naturals acquires Midwest Ketafusion.

Redlight Holland imports psilocybin into Saint Vincent and the Grenadines.

Optimi Health begins psilocybin mushroom cultivation.

Psychedelic-assisted therapy in the metaverse.

The brave new world of psychedelics is already here.

PSYCH Symposium: London 2022

PSYCH Symposium brings leading figures from policy, science and business together to shape the future of psychedelic healthcare in Europe.

Speakers include:

Amanda Feilding – Founder, Beckley Foundation
Bryan Roth – Lead, Defense Advanced Research Projects Agency (DARPA)
Benjamin Lightburn – CEO, Filament Health

Secure your ticket today to connect with industry influencers and learn from the sector’s thought leaders, as we expedite access to psychedelic medicine.

For partnership opportunities, please visit the website.

Ticket registration

SCIENCE AND RESEARCH

AI analyses anecdotal reports to better understand the psychedelic experience.

Ketamine infusions for chronic pain.

Little evidence on psilocybin’s interaction with existing psychiatric treatments.

The promise of psychedelic medicines.

REGULATION AND LEGISLATION

Washington legislature approves $200,000 funding for psilocybin research.

Rescheduling psilocybin in the UK.

Connecticut lawmakers approve bill to establish psychedelic healthcare centres.

How psilocybin could follow in the footsteps of cannabis.

Pennsylvania psilocybin research bill faces opposition.